Quick facts

Company Description – ESA Biosciences, Inc. has a distinguished history of innovation, fueled by a desire to get answers for research problems, and solve specific applications challenges for customers. Originally named Environmental Sciences Associates, ESA was founded in 1968 by four recently graduated MIT PhDs who set out to develop an instrument to measure lead based on a novel electrochemical technique, called anodic stripping voltammetry, or ASV. The result was the first and only practical instrument specifically cleared by the U.S. Food and Drug Administration for measuring lead levels in children. Today, ESA designs and manufactures a full range of specialty high-performance liquid chromatography (HPLC) detectors, instruments, reagents, consumables, and total solutions – turnkey systems with all you need to achieve maximum performance: integrated components, including instruments, columns, reagents, and, in some cases, sample prep – along with expert chemistry, application, and service support. Our products can be found in virtually every type of clinical-diagnostic, biomedical-research, and industrial laboratory worldwide – from pharmaceutical research and quality control, to oncology, food and beverage, and scientific discovery. Through our subsidiary, ESA Laboratories, Inc., we also provide a range of analytical services – from industrial-hygiene and clinical-diagnostic analysis to metabolomics.

Headquartered about 30 miles northwest of Boston in Chelmsford, Massachusetts, ESA employs a talented, multidisciplinary staff of approximately 100 worldwide. These include design and service engineers, applications scientists, marketing specialists, and precision-manufacturing experts. Many hold advanced scientific or engineering degrees. Employees work cross-functionally to provide quick response to customers and to solve complex product-development and technical-support problems.

Ownership and financial information

A privately held company, Magellan Biosciences is majority-owned by Ampersand Ventures. Other investors include Abingworth Management, Boston Community Venture Fund, Hambrecht & Quist Capital Management, KBL Healthcare Ventures, New England Partners Capital LP, and Nexus Medical Partners II SICAR. As such, we do not release our company financials. Our goal is to deliver double-digit revenue growth, balanced between internal growth and acquisitions.

Executive management team

Ian Acworth, PhD – Vice President of HPLC Products and Services
Mark Bowers, PhD – Vice President Biosensor Technology
Paul Gamache, MA – Vice President of Applications Development
Jasmine Gruia-Gray, PhD – Vice President Life Sciences Marketing
Hossein Maleknia, MA – Vice President Operations
Chris Miles, MA – Vice President of Engineering
Michael S. Pettigrew – Vice President of Life Sciences Sales
James P. Whelan – Vice President Sales & Marketing, Clinical-
Diagnostic Products